← Search & browse all drugs
NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Ergot alkaloids
lisuride
N02CA07
Forms & Strengths
- Oral tablets: 0.2 mg
- Oral tablets: 0.5 mg
- Subcutaneous infusion: 5 mcg/mL
Adult Dosing
- Parkinson's disease: Initial 0.025 mg to 0.05 mg orally 2-3 times daily, titrated slowly to maintenance of 0.6 mg to 2 mg daily in divided doses
- Migraine prophylaxis: 0.025 mg to 0.05 mg orally 3 times daily
- Hyperprolactinemia: 0.05 mg to 0.2 mg orally 2-3 times daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of Parkinson's disease (monotherapy or as adjunct to levodopa)
- Prevention of vascular headaches and migraine
- Suppression of lactation and treatment of hyperprolactinemic disorders
Mechanism of Action
- Dopamine receptor agonist (partial or full agonist at D2, D3, and D4 receptors)
- Serotonin receptor modulator (agonist/antagonist properties at 5-HT1 and 5-HT2 receptors)
- Ergot alkaloid derivative with central sympatholytic activity
Contraindications
- Hypersensitivity to lisuride or other ergot alkaloids
- Uncontrolled hypertension
- History of valvular heart disease or fibrotic disorders
- Severe ischemic heart disease or peripheral vascular disease
Adverse Reactions
- Nausea, vomiting, and gastrointestinal upset
- Orthostatic hypotension and dizziness
- Somnolence, sudden onset of sleep, and hallucinations
- Dyskinesias (when used with levodopa)
- Rare: Pleuropulmonary, retroperitoneal, or cardiac valve fibrosis with long-term use
Drug Interactions
- Dopamine antagonists (e.g., antipsychotics, metoclopramide) antagonize therapeutic effects
- Antihypertensive agents may lead to additive hypotensive effects
- Strong CYP3A4 inhibitors may increase plasma concentrations of lisuride
- Other ergot derivatives increase risk of ergotism and vasoconstrictive events
Curated Content: Needs Vetting Before Put to Clinical Use